Published Date:	Saturday 1st December, 2018	Publication:	The Financial Express [Bangalore]
Journalist:	Bloomberg	Page No:	6
MAV/CCM:	7,680/6.4	Circulation:	15,444

Biocon, Mylan joint product gets EU nod

Biotechnology major Biocon on Friday said the European Commission has granted marketing authorisation to its partner Mylan for Fulphila, a biosimilar product to treat cancer. Fulphila, a biosimilar Pegfilgrastim, jointly developed by Biocon and Mylan, has been approved in the European Union.